703 related articles for article (PubMed ID: 31388127)
1. Clinical actionability of molecular targets in endometrial cancer.
Urick ME; Bell DW
Nat Rev Cancer; 2019 Sep; 19(9):510-521. PubMed ID: 31388127
[TBL] [Abstract][Full Text] [Related]
2. Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations.
Conlon N; Da Cruz Paula A; Ashley CW; Segura S; De Brot L; da Silva EM; Soslow RA; Weigelt B; DeLair DF
Am J Surg Pathol; 2020 May; 44(5):641-648. PubMed ID: 32205482
[TBL] [Abstract][Full Text] [Related]
3. Molecular Genetics of Endometrial Carcinoma.
Bell DW; Ellenson LH
Annu Rev Pathol; 2019 Jan; 14():339-367. PubMed ID: 30332563
[TBL] [Abstract][Full Text] [Related]
4. Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases.
Köbel M; Meng B; Hoang LN; Almadani N; Li X; Soslow RA; Gilks CB; Lee CH
Am J Surg Pathol; 2016 Feb; 40(2):166-180. PubMed ID: 26492180
[TBL] [Abstract][Full Text] [Related]
5. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses.
McAlpine J; Leon-Castillo A; Bosse T
J Pathol; 2018 Apr; 244(5):538-549. PubMed ID: 29344951
[TBL] [Abstract][Full Text] [Related]
6. Endometrial cancers in mutation carriers from hereditary breast ovarian cancer syndrome kindreds: report from the Creighton University Hereditary Cancer Registry with review of the implications.
Casey MJ; Bewtra C; Lynch HT; Snyder CL; Stacey M
Int J Gynecol Cancer; 2015 May; 25(4):650-6. PubMed ID: 25756400
[TBL] [Abstract][Full Text] [Related]
7. The mutational landscape of endometrial cancer.
Hong B; Le Gallo M; Bell DW
Curr Opin Genet Dev; 2015 Feb; 30():25-31. PubMed ID: 25622247
[TBL] [Abstract][Full Text] [Related]
8. Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.
Reitsma W; Mourits MJ; de Bock GH; Hollema H
Mod Pathol; 2013 Apr; 26(4):572-8. PubMed ID: 23080033
[TBL] [Abstract][Full Text] [Related]
9. High-grade endometrial carcinomas: Morphologic spectrum and molecular classification.
Zhang C; Zheng W
Semin Diagn Pathol; 2022 May; 39(3):176-186. PubMed ID: 34852949
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
11. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of tumor budding in endometrial carcinoma within distinct molecular subgroups.
Rau TT; Bettschen E; Büchi C; Christe L; Rohner A; Müller MD; Carlson JW; Imboden S; Zlobec I
Mod Pathol; 2021 Jan; 34(1):222-232. PubMed ID: 32728223
[TBL] [Abstract][Full Text] [Related]
13. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms.
Tafe LJ; Garg K; Chew I; Tornos C; Soslow RA
Mod Pathol; 2010 Jun; 23(6):781-9. PubMed ID: 20305618
[TBL] [Abstract][Full Text] [Related]
14. The genetic landscape of endometrial clear cell carcinomas.
DeLair DF; Burke KA; Selenica P; Lim RS; Scott SN; Middha S; Mohanty AS; Cheng DT; Berger MF; Soslow RA; Weigelt B
J Pathol; 2017 Oct; 243(2):230-241. PubMed ID: 28718916
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of molecular characteristics into endometrial cancer management.
Vermij L; Smit V; Nout R; Bosse T
Histopathology; 2020 Jan; 76(1):52-63. PubMed ID: 31846532
[TBL] [Abstract][Full Text] [Related]
16. PRAME Expression in Endometrioid and Serous Endometrial Carcinoma: A Potential Immunotherapeutic Target and Possible Diagnostic Pitfall.
Coppock JD; Gradecki SE; Mills AM
Int J Gynecol Pathol; 2023 Jan; 42(1):35-42. PubMed ID: 35512215
[TBL] [Abstract][Full Text] [Related]
17. Markers for individualised therapy in endometrial carcinoma.
Salvesen HB; Haldorsen IS; Trovik J
Lancet Oncol; 2012 Aug; 13(8):e353-61. PubMed ID: 22846840
[TBL] [Abstract][Full Text] [Related]
18. [Histological and molecular classification of endometrial carcinoma and therapeutical implications].
Genestie C; Leary A; Devouassoux M; Auguste A
Bull Cancer; 2017 Dec; 104(12):1001-1012. PubMed ID: 29031505
[TBL] [Abstract][Full Text] [Related]
19. Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression.
Westin SN; Broaddus RR; Deng L; McCampbell A; Lu KH; Lacour RA; Milam MR; Urbauer DL; Mueller P; Pickar JH; Loose DS
Cancer Biol Ther; 2009 Nov; 8(22):2126-35. PubMed ID: 19755863
[TBL] [Abstract][Full Text] [Related]
20. A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas.
Wang M; Hui P
Arch Pathol Lab Med; 2021 Nov; 145(11):1367-1378. PubMed ID: 34673912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
